We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA Seeks Input on Requirements for Orphan Medicine Designation
EMEA Seeks Input on Requirements for Orphan Medicine Designation
February 17, 2009
The European Medicines Agency’s (EMEA) Committee for Orphan Medicinal Products (COMP) has released a draft discussion paper outlining the level of evidence required to support an orphan medicines designation.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor